deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT03691376

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sponsor: Roswell Park Cancer Institute

Conditions Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Ovarian Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Platinum-Sensitive Fallopian Tube Carcinoma Platinum-Sensitive Ovarian Carcinoma Platinum-Sensitive Primary Peritoneal Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Refractory Fallopian Tube Carcinoma Refractory Ovarian Carcinoma Refractory Primary Peritoneal Carcinoma
Interventions Aldesleukin Autologous NY-ESO-1-specific CD8-positive T Lymphocytes Cellular Therapy Melphalan
Updated 24 times since 2018 Last updated: Sep 6, 2024 Started: Mar 8, 2019 Primary completion: Jan 30, 2021 Completion: Jun 24, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of funding

Other terminated trials from Roswell Park Cancer Institute

See all terminations from Roswell Park Cancer Institute

Listed as NCT03691376, this PHASE1 trial focuses on Platinum-Resistant Fallopian Tube Carcinoma and Platinum-Resistant Ovarian Carcinoma and remains terminated or withdrawn. Sponsored by Roswell Park Cancer Institute, it has been updated 24 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jan 2020 · 8 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Jun 2022 · 12 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – present · 22 months · monthly snapshot

Change History

24 versions recorded

  1. Oct 2024 — Present [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  2. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 19 earlier versions

  1. Aug 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Jun 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  6. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  7. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  8. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  9. Jun 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  10. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  11. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE1

  12. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE1

  13. May 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  14. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1

  15. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  16. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  17. Jan 2019 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE1

  18. Dec 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE1

  19. Nov 2018 — Dec 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Roswell Park Cancer Institute
Data source: Roswell Park Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations